CARE™ Congress 2018

The second National CARE™ Congress was a great success! Thank you to all those who attended.

The second National CARE™ Congress: Update on Biosimilars and Access to Innovation was held at the Shangri-La Hotel in Toronto on April 6th, 2018. The meeting addressed questions and considerations regarding biosimilars in Canada and how they build towards a larger discussion on access to innovative medicine. The meeting included discussion and provided a platform for medical specialists and key stakeholders across multiple fields to meet, collaborate, and discuss concepts that have a practical impact on the Canadian healthcare landscape.

The Aim

The CARE™ Congress aims to allow assembled CARE™ faculty and panelists to consider the use of biosimilars and align on the importance of access to innovation.

The CARE™ Faculty is pleased to welcome a robust speaker line-up, with representation from Canadian researchers, clinicians, government,  public and private funding agencies, health economists, hospital pharmacists, nurses, advocacy groups, ethicists and legal experts.


Friday, April 6th, 2018
Registration & Lunch 11:15 – 12:00 pm
Meeting Sessions 12:00 – 5:00 pm


John Marshall, MD – McMaster University
John Kuruvilla, MD – Princess Margaret Cancer Centre


Shangri-La Hotel,
188 University Ave, Toronto, ON
Queens Park South Meeting Room

Event Feedback

Section 1: Update on Biosimilars

The first section of the 2018 CARE™ Congress on Biosimilars and Access to Innovation focused on biosimilars. After an opening from the Congress Chairs, Dr. John Marshall and Scott Edwards presented on CARE™ education initiatives in biosimilars and gaps in knowledge that still exist in Canada. This was followed by a multidisciplinary discussion.

Section 2: Access to Innovation

In the second section of the 2018 CARE™ Congress, participants were involved in the following four plenary sessions on access to innovation: Translational Science & Innovation to Access, Drug Approval and Public Pricing, Private Payer Perspectives, and Patient Perspectives. Multi-stakeholder discussions took place after the first three presentations.

Plenary Session 1:

Plenary Session 2:

Plenary Session 3:

Plenary Session 4: